StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
DMAADrugs Made In America Acquisition Corp.
stockpulse.co.kr
Nasdaq
$10.88▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $264.0MShares out 24.3M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 3d agoAfter-hours26.10.22 06:29
    425Other#●●●#●●●

    Drugs Made In America Acquisition Corp.

    Drugs Made In America Acquisition Corp. has amended its merger agreement with Power Analytics Global Corp (PAGC), setting a standalone closing valuation of $1.71 billion if the APQC Acquisition is not completed by November 1, 2026, down from the original $2.85 billion. Additionally, the company terminated its previous fairness opinion engagement and appointed Joel A. Gallo as an independent evaluator to provide a fairness opinion on the $1.71 billion standalone valuation.…more

    $10.88+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 3d agoAfter-hours26.10.22 06:27
    8-KKey event

    Drugs Made In America Acquisition Corp.

    DMAA has amended its merger agreement with Power Analytics Global Corp (PAGC) to automatically adjust the closing valuation from $2.85 billion to $1.71 billion if the APQC Acquisition is not completed by November 1, 2026. Additionally, the company terminated its previous fairness opinion provider and engaged Joel A. Gallo as an independent evaluator, with the opinion on the $1.71 billion valuation expected by October 26, 2026.…more

    $10.88+0.00%vs prev close
    View filingShare
  • 9.14After-hours26.09.15 05:32
    425Other

    Drugs Made In America Acquisition Corp.

    Drugs Made In America Acquisition Corp. (DMAA) entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp (PAGC) on September 8, 2026. The transaction fixes the closing valuation at $2.85 billion, with DMAA domesticating to Delaware and merging with PAGC to continue as a Nasdaq-listed entity. Closing is subject to conditions including a minimum of $15 million in available cash and the completion of PAGC's acquisition of APQC.…more

    $10.88+0.00%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire

No news collected yet. New articles will appear here.